Skip to main content

Table 1 Baseline characteristics, intent-to-treat population

From: Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

Characteristic Cohort 1: pertuzumab, trastuzumab, and vinorelbine N = 106
Median age, years (range) 56 (30–82)
Female gender 106 (100%)
Geographical region
 Europe 91 (85.8%)
 North America 15 (14.2%)
ECOG performance status
 0 74 (69.8%)
 1 32 (30.2%)
Disease type at screening
 Visceral 78 (73.6%)
 Non-visceral 28 (26.4%)
Disease stage at initial diagnosis
 I 12 (11.3%)
 II 31 (29.2%)
 III 29 (27.4%)
 IV 34 (32.1%)
Disease stage at advanced breast cancer diagnosis
 Locally advanced 11 (10.4%)
 Metastatic 95 (89.6%)
Hormone receptor status
 Estrogen and/or progesterone receptor-positive 70 (66.0%)
 Estrogen and progesterone receptor-negative 36 (34.0%)
HER2 status, local assessment
 Immunohistochemistry  
  0 or 1+ 0
  2+ 14 (13.2%)
  3+ 85 (80.2%)
  Not performed 7 (6.6%)
 In situ hybridization
  Positive 26 (24.5%)
  Negative 0
  Not performed 80 (75.5%)
HER2 status, central assessment
 HER2-positive 88 (83.0%)
 HER2-negative 12 (11.3%)
 Not done 2 (1.9%)
 Missing 4 (3.8%)
 Immunohistochemistry
  0 or 1+ 8 (7.5%)
  2+ 17 (16.0%)
  3+ 75 (70.8%)
  Not performed 2 (1.9%)
  Missing 4 (3.8%)
 In situ hybridization
  Positive 80 (75.5%)
  Negative 8 (7.5%)
  Not performed 3 (2.8%)
  Not evaluable 11 (10.4%)
  Missing 4 (3.8%)
Prior systemic cancer therapy 65 (61.3%)
 Taxanea 40 (37.7%)
 Anthracyclineb 41 (38.7%)
 Trastuzumab 44 (41.5%)
 Bevacizumab 1 (0.9%)
  1. Data are number (%).
  2. aPaclitaxel, docetaxel, nab-paclitaxel, or taxane (not otherwise specified)
  3. bEpirubicin, doxorubicin, mitoxantrone, or anthracycline (not otherwise specified)